Medical Experts Rename Common Women's Health Condition After 14-Year Global Campaign
Global, 14 May 2026
Polycystic ovary syndrome, affecting one in eight women worldwide, has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome following a landmark 14-year international effort involving over 22,000 patient responses. The change addresses decades of diagnostic confusion caused by the misleading original name, which focused incorrectly on ovarian cysts rather than the condition’s complex hormonal and metabolic impacts including diabetes, heart disease, and mental health issues affecting 170 million women globally.
Global Medical Consensus Emerges After Extensive Research
The formal announcement of the name change was published in The Lancet on 11 May 2026, marking the culmination of an unprecedented international collaboration [2][3]. The effort involved more than 50 patient and professional organisations, including the Endocrine Society, which represents over 18,000 members across 133 countries [2]. The research process included over 22,000 survey responses and international workshops to ensure the new name would benefit patients whilst maintaining scientific accuracy [2]. Dr Helena Teede, an endocrinologist and professor of women’s health at Monash University who led the initiative, explained that ‘the agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation’ [2].
Understanding the Widespread Impact of PMOS
The World Health Organisation estimates that 10% to 13% of reproductive-age women globally are affected by this condition, yet approximately 70 per cent remain undiagnosed [1]. The syndrome extends far beyond reproductive health, causing irregular menstrual cycles, difficulty conceiving, female-pattern baldness, type 2 diabetes, cardiovascular disease, sleep apnoea, depression, anxiety, and body dysmorphia [1][2]. Research indicates PMOS significantly increases the risk of liver and heart disease, highlighting why the condition required a name that accurately reflects its metabolic complexity [1]. The original terminology created confusion because, as Dr Alla Vash-Margita from Yale University noted, ‘there was a lot of stigma and myth related to this name. People thought they have large cysts, which they do not have’ [1].
Why the Original Name Proved Problematic
The term ‘polycystic’ was fundamentally inaccurate because the structures observed in affected ovaries are arrested follicles, not cysts [3]. The National Institutes of Health recognised this issue as early as 2012, stating that ‘the name focuses on a criterion — polycystic ovarian morphology — which is neither necessary nor sufficient to diagnose the syndrome’ [3]. Dr Teede emphasised that ‘by calling this condition polycystic ovary, we’re missing the big picture’ [1]. The condition was initially understood as a reproductive disorder linked to elevated male hormone levels, but research in the 1980s revealed its association with insulin resistance, fundamentally changing medical understanding [1]. Surveys conducted during the renaming process revealed that 86 per cent of patients and 76 per cent of health professionals agreed the PCOS name should change [3].
Implementation Timeline and Healthcare Access
The new PMOS terminology will be fully implemented in the 2028 International Guideline update, supported by a three-year international education and awareness campaign beginning in 2026 [2]. For patients seeking diagnosis, healthcare providers will check hormone levels for insulin resistance or elevated androgen levels [1]. Current treatments focus on managing symptoms through lifestyle modifications including balanced diet and increased exercise, medications for metabolic symptoms such as GLP-1s, birth control pills, and fertility treatments where appropriate [1]. Dr Christina Boots from Northwestern’s Feinberg School of Medicine highlighted the importance of comprehensive care, noting that effective treatment requires ‘finding healthcare providers who can take the time to view the whole picture and make good referrals to create a plan’ [1]. The name change aims to reduce the fragmented approach where ‘somebody’s dietitian tells them one thing, and their psychiatrist tells them another thing, and their dermatologist tells them another, so they’ve got so many players who are in their niche and often don’t see the full picture’ [1].